Get the Stockscreener App
3.515
0.29%
0.015
Compass Therapeutics Inc stock is traded at $3.515, with a volume of 529.04K.
It is up +0.29% in the last 24 hours and up +145.45% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
See More
Previous Close:
$3.50
Open:
$3.62
24h Volume:
529.04K
Relative Volume:
0.44
Market Cap:
$481.56M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-10.04
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+9.01%
1M Performance:
+145.45%
6M Performance:
+290.00%
1Y Performance:
+161.94%
1-Day Range:
$3.47
$3.635
1-Week Range:
$2.97
$3.65
52-Week Range:
$0.765
$3.65
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.52 | 481.56M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.12 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.15 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.65 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 5.2% in January - MarketBeat
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Taking on analysts’ expectations and winning: Compass Therapeutics Inc (CMPX) - SETE News
Compass Therapeutics Inc (NASDAQ: CMPX) Stock Gained 116.67% Over A Month – Any Room To Run? - Marketing Sentinel
3 Penny Stocks On US Exchanges With Market Caps Under $500M - Simply Wall St
BlackRock, Inc. Increases Stake in Compass Therapeutics Inc - GuruFocus.com
How to interpret Compass Therapeutics Inc (CMPX)’s stock chart patterns - US Post News
Analytical Lens: Exploring Compass Therapeutics Inc (CMPX)’s Financial Story Through Ratios - The Dwinnex
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - Defense World
Top 3 High-Momentum Companies Analysts Are Still Bullish On - Investing.com
Top 3 High-Momentum Companies Analysts Are Still Bullish On - sharewise
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025 - Yahoo Finance
Best Penny Stocks to Watch in February 2025, Using Technical Analysis - Investopedia
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - MSN
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by SG Americas Securities LLC - Defense World
SG Americas Securities LLC Raises Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics stock hits 52-week high at $3.14 - MSN
Biliary Tract Cancer Market Poised for Significant Growth from - openPR
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Compass Therapeutics stock hits 52-week high at $3.14 By Investing.com - Investing.com South Africa
VF Corp (VFC) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Can Compass Therapeutics' Tovecimig Chart A New Direction In The Treatment Of Biliary Tract Cancers? - RTTNews
Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Insider Monkey
Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2% - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Barclays PLC - Defense World
Barclays PLC Purchases 112,614 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - MarketBeat
2025 catalysts: Bispecifics poised to enter new era - BioCentury
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Earns “Outperform” Rating from William Blair - Defense World
VerifyMe (NASDAQ: VRME) Enters Agreement with Institutional Investor for $4.7 Million Proceeds - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Alliance Global Partners Initiates Coverage on TMC the metals (NASDAQ:TMC) - Defense World
Compass Therapeutics stock hits 52-week high at $2.68 - MSN
TANG CAPITAL MANAGEMENT LLC Increases Stake in Compass Therapeutics Inc - GuruFocus.com
Compass Therapeutics stock hits 52-week high at $2.68 By Investing.com - Investing.com UK
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Jane Street Group LLC Trims Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Biliary Tract Cancer Market Expected to Experience Major Growth - openPR
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
KBW Regional Banking Index (KRX) QuotePress Release - The Globe and Mail
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate - GlobeNewswire
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):